PMID- 23485810 OWN - NLM STAT- MEDLINE DCOM- 20131017 LR - 20240109 IS - 1873-7544 (Electronic) IS - 0306-4522 (Linking) VI - 238 DP - 2013 May 15 TI - Protective effect of creatine against 6-hydroxydopamine-induced cell death in human neuroblastoma SH-SY5Y cells: Involvement of intracellular signaling pathways. PG - 185-94 LID - S0306-4522(13)00164-4 [pii] LID - 10.1016/j.neuroscience.2013.02.030 [doi] AB - The guanidine-like compound creatine exerts bioenergetic, antiexcitotoxic, antioxidant and neuroprotective properties; however, the intracellular mechanisms responsible for these effects are still not well established. The purpose of this study was to investigate the protective effect of creatine against 6-hydroxydopamine (6-OHDA)-induced cell death in neuroblastoma SH-SY5Y cells and the possible intracellular signaling pathways involved in such effect. Exposure of SH-SY5Y cells to 100-300muM of 6-OHDA for 24h caused a significant concentration-dependent cell death measured as a diminution of 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl-tetrazolium bromide (MTT) reduction and as an increase in the extracellular release of lactate dehydrogenase. SH-SY5Y cells incubated for 24 or 48h with creatine (10-5000muM) was not cytotoxic. However, pre and co-treatment with creatine (0.3-1000muM) for 24h reduced 6-OHDA-induced toxicity. The protective effect afforded by creatine against 6-OHDA-induced toxicity was reversed by inhibitors of different protein kinases, i.e. phosphatidylinositol-3 kinase (PI3K) (LY294002), Ca(2+)/calmodulin-dependent protein kinase II (CaMKII) (KN-93), protein kinase A (H-89), mitogen-activated protein kinase kinase 1/2 (MEK1/2) (PD98059) and protein kinase C (PKC) (chelerythrine). Furthermore, creatine prevented the 6-OHDA-induced dephosphorylation of glycogen synthase kinase-3beta (GSK-3beta) at the serine 9 residue. In conclusion, the results of this study show that creatine can protect against 6-OHDA-induced toxicity and its protective mechanism is related to a signaling pathway that involves PI3K, PKC, PKA, CaMKII, MEK1/2 and GSK-3beta. CI - Copyright (c) 2013 IBRO. Published by Elsevier Ltd. All rights reserved. FAU - Cunha, M P AU - Cunha MP AD - Instituto Teofilo Hernando, Facultad de Medicina, Universidad Autonoma de Madrid, 4-28029 Madrid, Spain. mauricio.personal@gmail.com FAU - Martin-de-Saavedra, M D AU - Martin-de-Saavedra MD FAU - Romero, A AU - Romero A FAU - Parada, E AU - Parada E FAU - Egea, J AU - Egea J FAU - Del Barrio, L AU - Del Barrio L FAU - Rodrigues, A L S AU - Rodrigues AL FAU - Lopez, M G AU - Lopez MG LA - eng PT - Journal Article PT - Research Support, Non-U.S. Gov't DEP - 20130226 PL - United States TA - Neuroscience JT - Neuroscience JID - 7605074 RN - 8HW4YBZ748 (Oxidopamine) RN - MU72812GK0 (Creatine) SB - IM MH - Cell Death/*drug effects MH - Cell Line, Tumor MH - Cell Survival/drug effects MH - Creatine/*pharmacology MH - Dose-Response Relationship, Drug MH - Humans MH - Neuroblastoma/metabolism/*pathology MH - Neurons/*drug effects/metabolism/pathology MH - Oxidopamine/*pharmacology MH - Phosphorylation/drug effects MH - Signal Transduction/*drug effects EDAT- 2013/03/15 06:00 MHDA- 2013/10/18 06:00 CRDT- 2013/03/15 06:00 PHST- 2012/09/24 00:00 [received] PHST- 2013/02/15 00:00 [revised] PHST- 2013/02/15 00:00 [accepted] PHST- 2013/03/15 06:00 [entrez] PHST- 2013/03/15 06:00 [pubmed] PHST- 2013/10/18 06:00 [medline] AID - S0306-4522(13)00164-4 [pii] AID - 10.1016/j.neuroscience.2013.02.030 [doi] PST - ppublish SO - Neuroscience. 2013 May 15;238:185-94. doi: 10.1016/j.neuroscience.2013.02.030. Epub 2013 Feb 26.